UCB, ImClone to jointly develop anti-tumor antibody

UCB and ImClone Systems have joined forces to develop CDP-791, an antibody targeting blood-vessel growth in tumors that recently passed Phase I trials. A Phase II study of the treatment is set to begin within weeks. The agreement calls for UCB and ImClone to share development costs -- and eventual profits -- equally. "This is an important milestone in the building of UCB's oncology franchise," stated Melanie Lee, executive vice president R&D for UCB.

- read this press release for more

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.